Navigation Links
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:5/12/2008

for our planned trials in a timely manner; our need for capital, which may not be available on a timely basis, or at all; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for obtaining clinical supply materials; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that immunology responses are a predictor of clinical benefit; that immunological findings in our first three cohorts will be consistent with findings from our fourth cohort and future clinical studies; that safety and tolerability findings in all four cohorts will be consistent with findings from future clinical studies; that results from future clinical trials will be consistent with our expectations; that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and Poly-ICLC in a timely manner; that sufficient HspE7 and Poly-ICLC will be available to conduct our planned clinical trials; that we will obtain timely approval from additional Investigational Review Boards; that the results from additional preclinical and clinical work, if any, will be consist
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... OAKS, Calif. , May 16, 2013  Amgen (NASDAQ: ... Life Sciences Conference on Tuesday, May 21, 2013, at the ... City , beginning at 10:00 a.m. Eastern Daylight Time. ... vice president of Research and Development at Amgen, will present ... accessed from the Events Calendar on Amgen,s website, www.amgen.com ...
(Date:5/16/2013)... , May 16, 2013 ... in the U.S. to access the widely-used OrthoView digital ... PC and Internet connection to get started. ... software for over 10 years, is dedicated to enabling ... with digital x-ray images, when printed film is unavailable. ...
(Date:5/16/2013)... , May 16, 2013 Developers of a pill ... reminders have emerged as grand prize winners in the ... funded by Boehringer Ingelheim and organized by HITLAB . ... , John Langhauser and ... the United States will receive $50,000 ...
Breaking Medicine Technology:OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 2Wireless Pill Bottle Wins Healthcare Innovation World Cup 3Wireless Pill Bottle Wins Healthcare Innovation World Cup 4Wireless Pill Bottle Wins Healthcare Innovation World Cup 5
... Johnson & Johnson Pharmaceutical,Research & Development, L.L.C. ... showed that investigational antibiotic ceftobiprole was found to,clinically ... -- including,some infections that were caused by methicillin-resistant ... the 45th annual meeting of the Infectious,Disease Society ...
... 3 clinical development program will examine HZT-501 as ... NSAID for mild to moderate pain -, ... Inc., a,privately held biopharmaceutical company, today announced that ... (protocol HZ-CA-304) of its lead,product candidate HZT-501, an ...
Cached Medicine Technology:New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 2New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 3New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections 4Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501 2Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501 3
(Date:5/19/2013)... May 19, 2013 According to ... Analysis and Forecast (2013 – 2018): By Applications ... Industrial)); Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) ... image sensor market was $8.00 billion in 2012 ... 2018, at an estimated CAGR of 3.84% from ...
(Date:5/19/2013)... New York, New York (PRWEB) May 19, 2013 ... note that a Case Management Conference was recently convened ... in a federal multidistrict litigation now underway in U.S. ... Minutes posted on the Court’s website on May 14th, ... motions. It was also reported during the Conference ...
(Date:5/19/2013)... Vegas Hotel Escapes, the premier Las ... launch it's all new vacation packages for the upcoming ... Consumers traveling to Las Vegas will be pleased to ... website. Travelers will be pleased to know that VegasHotelEscapes.com ... Vegas Hotel Escapes specializes in helping consumers Las ...
(Date:5/19/2013)... Beginning Wednesday, May 29 and running through Wednesday, August ... “Hot Dog Wednesdays" and Ice Cold Slushies at donor centers ... and all the fixin's to donors on Wednesdays. RRVBC ... “Donors are our lifeline. The summer months are an especially ... This is a small way for us to thank ...
(Date:5/19/2013)... The legal team at Pulaski & ... concerted effort to connect women and families coping with ... Yaz, Yasmin & Ocella with the legal representation they ... the notorious birth control drugs as well as news ... Yaz, Yasmin & Ocella were very popular birth control ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... Live Event ... Optimize Available Resources , ... VA (PRWEB) May 11, 2010 -- Harmony Information Systems Inc ., the leader in ... Vermont and Pennsylvania Are Taking Control of Medicaid Waivers Management ,” scheduled for Wednesday, May ...
... ... an Interpretive Dance Video. , ... Seattle, WA (PRWEB) May 11, 2010 -- Onlineshoes.com is proud to announce ... campaign featuring an interpretive dance video. , , ,Pronounced “cushy”, Cushe is a ...
... ... been recognized as a silver SugarCRM implementation partner providing best-practice implementation services ... the last two years as a leading player in producing advanced sales and marketing ... ...
... Melanoma and ... is linked to cancer risk. Practical and clinical information about skin health, melanoma and skin ... , ... -- With skin cancer on the rise for Americans under 30 and indoor tanning contributing ...
... ... million in a medical malpractice case against an obstetrician who delayed a C-section while the baby ... Division, Essex County, Docket No.: ESX-L-1906-08. , ... (PRWEB) May 11, 2010 -- On April 29, 2010 an Essex County, New Jersey jury ...
... ... noise , ... 11, 2010 -- Noisy construction by the MTA is keeping some residents in Brooklyn up ... have had no effect. Construction accident attorneys in New York are familiar with the ...
Cached Medicine News:Health News:Harmony Information Systems to Host Free Webcast: Learn How Vermont and Pennsylvania Are Taking Control of Medicaid Waivers Management 2Health News:Harmony Information Systems to Host Free Webcast: Learn How Vermont and Pennsylvania Are Taking Control of Medicaid Waivers Management 3Health News:Onlineshoes.com and Cushe Team Up to Offer Men and Women Shoes for Casual Living 2Health News:Onlineshoes.com and Cushe Team Up to Offer Men and Women Shoes for Casual Living 3Health News:ApexTwo and SugarCRM Announce New Implementation Partnership 2Health News:Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians 2Health News:Skincancer.com Launches With Latest News, Information and Help for Consumers/Patients and Physicians 3Health News:$18.5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C-Section 2Health News:New York Construction Accident Attorney, David Perecman, Supports MTA Night Work 2
Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
... Burgdorferi Antibody Detection Assay is a single ... presumptive (first step) detection of IgG and ... serum or whole blood. Rapid turnaround time, ... the Wampole PreVue B. burgdorferi antibody detection ...
Medicine Products: